Cargando…

Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report

Atopic dermatitis (AD) is a common inflammatory skin disease, which negatively impacts the individual’s quality of life (QoL). In particular, moderate-to-severe AD is frequently difficult to treat. We report a case involving a 40-year-old male who has suffered from AD since early childhood and who a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moennig, Eva, Traidl, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789715/ https://www.ncbi.nlm.nih.gov/pubmed/36573170 http://dx.doi.org/10.2147/CCID.S382424

Ejemplares similares

Atopic dermatitis treated with tralokinumab and upadacitinib combination therapy: A case report
por: Lansang, Rafael Paolo, et al.
Publicado: (2023)

Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study
por: De Greef, Axel, et al.
Publicado: (2023)

Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
por: Soehoel, Anders, et al.
Publicado: (2022)

Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data
por: Kelly, Katherine A, et al.
Publicado: (2022)

Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis: A Secondary Analysis
por: Merola, Joseph F., et al.
Publicado: (2023)

Skin Barrier and Inflammation Genes Associated with Atopic Dermatitis are Regulated by Interleukin-13 and Modulated by Tralokinumab In vitro
por: TOLLENAERE, Maxim A. X., et al.
Publicado: (2021)

Efficacy and safety of tralokinumab in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials
por: Zhao, Dan-Jie, et al.
Publicado: (2023)

Recalcitrant Palmar-Plantar Atopic Dermatitis Successfully Treated with Dupilumab: A Case Series
por: Deng, Lin, et al.
Publicado: (2022)

Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis
por: Yayli, Savas, et al.
Publicado: (2013)

Janus kinase inhibitors for the therapy of atopic dermatitis
por: Traidl, Stephan, et al.
Publicado: (2021)

Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2023)

Recalcitrant erythrodermic ichthyosis with atopic dermatitis successfully treated with Dupilumab in combination with Guselkumab
por: Steinhoff, M., et al.
Publicado: (2021)

Autologous Immunoglobulin Therapy in Patients With Severe Recalcitrant Atopic Dermatitis: A Preliminary Report
por: Nahm, Dong-Ho, et al.
Publicado: (2014)

Remarkable response to dupilumab in a 5-year-old patient with severe, recalcitrant atopic dermatitis
por: Johnson, Brian B., et al.
Publicado: (2019)

Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
por: Simpson, Eric L., et al.
Publicado: (2023)

Tralokinumab: First Approval
por: Duggan, Sean
Publicado: (2021)

Differences in Genetic Variations Between Treatable and Recalcitrant Atopic Dermatitis in Korean
por: Jun, Myungsoo, et al.
Publicado: (2018)

Patient Journey in Atopic Dermatitis: The Real-World Scenario
por: Carrascosa, Jose Manuel, et al.
Publicado: (2021)

Real-World Experience of Long-Term Dupilumab Treatment for Atopic Dermatitis in Korea
por: Lee, Dong Hun, et al.
Publicado: (2022)

Thalidomide Responsive Recalcitrant Adult-Onset Atopic Dermatitis – Repurposing an Old Drug
por: Yadav, Vidya, et al.
Publicado: (2023)

Correction to: Tralokinumab: First Approval
por: Duggan, Sean
Publicado: (2021)

Correction to: Tralokinumab: First Approval
por: Duggan, Sean
Publicado: (2021)

Real-world treatment patterns for atopic dermatitis in South Korea
por: Lee, Ji Hyun, et al.
Publicado: (2022)

Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
por: Silverberg, Jonathan I., et al.
Publicado: (2022)

Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials
por: Simpson, Eric L., et al.
Publicado: (2022)

Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Moderate‐to‐severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real‐world experience
por: Stingeni, L., et al.
Publicado: (2022)

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis
por: Kamata, Masahiro, et al.
Publicado: (2021)

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial
por: Silverberg, J.I., et al.
Publicado: (2021)

Status report on the atopic dermatitis registry TREATgermany
por: Siegels, Doreen, et al.
Publicado: (2021)

Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry
por: LARSEN, Henrik H. P., et al.
Publicado: (2022)

Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience
por: ROGNER, Danielle, et al.
Publicado: (2022)

Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre
por: Kreeshan, Firas Constantin, et al.
Publicado: (2020)

Perception and Experience of Dupilumab in Atopic Dermatitis: A Real-Life Study
por: Antoine, Léa, et al.
Publicado: (2023)

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)
por: Wollenberg, A., et al.
Publicado: (2020)

Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study
por: Zhou, Bingjing, et al.
Publicado: (2022)

A rare skin infection in atopic dermatitis: A case report
por: Malara, Giovanna, et al.
Publicado: (2020)

Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

The Effectiveness and Safety of Dupilumab for the Treatment of Recalcitrant Chronic Actinic Dermatitis: A Case Series
por: Chen, Jiaoquan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qs7cdn7e2jll3svsqrq18vbfrk